SCHEMBL1580452

SCHEMBL1580452

COC(=O)c1ccc2c(c1Cl)CN(S(=O)(=O)c1ccc(C)cc1)N2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
RECQL P46063 1/20 0.39
MMP2 P08253 2/20 0.38
ANPEP P15144 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
FFAR4 Q5NUL3 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
CYP2C9 P11712 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPK1 P28482 2/20 0.36
HSD17B10 Q99714 2/20 0.36
HTT P42858 1/20 0.36
ALDH1A1 P00352 3/20 0.36
TSHR P16473 3/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12424564 0.68 CA12 (0.43) MAPTRECQLKMT2AMEN1FFAR4
SCHEMBL1580586 0.67 OPRM1 (0.47) MAPTRECQLKMT2AMEN1FFAR4
SCHEMBL21807392 0.67 FBP1 (0.53) MMP2ANPEPKMT2AMEN1FFAR4
SCHEMBL21875183 0.64 FBP1 (0.49) MMP2ANPEPKMT2AMEN1FFAR4
SCHEMBL18529851 0.64 MAPT (0.51) MAPTCA12CA1CA2CA9
SCHEMBL523584 0.63 ABL1 (0.57) MAPTCA12CA1CA2CA9
SCHEMBL9700742 0.63 MEN1 (0.51) MMP2ANPEPKMT2AMEN1FFAR4
SCHEMBL2732260 0.63 L3MBTL1 (0.44) MAPTKMT2AMEN1FFAR4CA12
SCHEMBL22748352 0.62 CA1 (0.47) MMP2ANPEPKMT2AMEN1CA12
SCHEMBL4268094 0.62 KDM4E (0.44) MAPTKMT2AFFAR4CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841462-B2 Bicyclic heterocycles as MEK kinase inhibitors GENENTECH, INC. 2014-09-23 US disclosed
US-20110190257-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS GENETECH, INC. (US) 2011-08-04 US disclosed
EP-2310373-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS Genentech, Inc. (US) 2011-04-20 EP disclosed
WO-2010003025-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS GENENTECH, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190257-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS MAP2K7, MAP3K1, MAP3K5 MAPT 4315/4885RECQL 2288/4885MMP2 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.